Author | Targeted Oncology Staff

Articles

Ease of Use With Subcutaneous Daratumumab Supplants the Intravenous Formulation as Standard of Care Across Settings in Myeloma

June 25, 2020

Article

In an interview with Targeted Therapies in Oncology, C. Ola Landgren, MD, PhD, discussed how the availability of daratumumab by subcutaneous administration will affect clinical practice going forward.

Sabari Examines Frontline and Second-Line Treatment Options in NSCLC

May 24, 2020

Article

Joshua K. Sabari, MD, goes through treatment options in the frontline and second-line for patients with non–small cell lung cancer in a Targeted Oncology case-based peer perspectives live discussion.

Gerber Addresses the Role of Mutations and Treatment in NSCLC at Different Stages

May 23, 2020

Article

In a Targeted Oncology case-based peer perspectives live discussion, David Gerber, MD, addresses the role of biomarkers in guiding treatment decisions for patients with non–small cell lung cancer based on a patient scenario.

FDA Approves Subcutaneous Daratumumab With Hyaluronidase in Multiple Myeloma Indications

May 01, 2020

Article

The FDA has approved the use of daratumumab in combination with hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The newly approved product allowed for subcutaneous dosing of daratumumab.